{"id":"chemotherapy-plus-p53","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Local injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3347606","moleculeType":"Small molecule","molecularWeight":"2109.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The p53 component is a gene therapy that delivers functional p53 tumor suppressor protein to cancer cells, restoring apoptosis and cell cycle control mechanisms that are often lost in tumors. When combined with chemotherapy, the restored p53 function can sensitize cancer cells to chemotherapy-induced DNA damage and increase treatment efficacy. This approach targets the fundamental p53 mutation or loss found in many human cancers.","oneSentence":"This combination therapy uses chemotherapy alongside a p53 gene therapy to restore tumor suppressor function and enhance cancer cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:17.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck cancer"},{"name":"Lung cancer"},{"name":"Other solid tumors with p53 deficiency"}]},"trialDetails":[{"nctId":"NCT07417761","phase":"PHASE2","title":"Tuvusertib in Astrocytoma With ATRX Mutation","status":"RECRUITING","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2025-12-19","conditions":"Astrocytoma","enrollment":56},{"nctId":"NCT04884282","phase":"PHASE2","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2021-10-12","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT05179447","phase":"NA","title":"PROfiling Based Endometrial Cancer Adjuvant Therapy","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2022-01-24","conditions":"Endometrial Cancer Stage I, Endometrial Cancer Stage II","enrollment":590},{"nctId":"NCT04277442","phase":"PHASE1","title":"Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT02098343","phase":"PHASE1, PHASE2","title":"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2014-03","conditions":"Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53","enrollment":247},{"nctId":"NCT03268382","phase":"PHASE2","title":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2017-07-31","conditions":"High-grade Serous Ovarian Cancer","enrollment":36},{"nctId":"NCT03654716","phase":"PHASE1","title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-11-01","conditions":"Leukemia, Brain Tumor, Solid Tumor","enrollment":21},{"nctId":"NCT04113122","phase":"NA","title":"Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-02-09","conditions":"Testicular Cancer","enrollment":192},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT03077243","phase":"PHASE2","title":"P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-12","conditions":"Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms","enrollment":195},{"nctId":"NCT06088030","phase":"PHASE2","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","status":"RECRUITING","sponsor":"Yang Li","startDate":"2023-12-13","conditions":"Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations","enrollment":50},{"nctId":"NCT03358017","phase":"PHASE2","title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-05","conditions":"Triple Negative Breast Cancer","enrollment":54},{"nctId":"NCT00082641","phase":"PHASE1, PHASE2","title":"Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-01-01","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT02099175","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Sinonasal Tumors","enrollment":41},{"nctId":"NCT02099188","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Unresectable Sinonasal Tumors","enrollment":27},{"nctId":"NCT05622058","phase":"PHASE1","title":"A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer","status":"TERMINATED","sponsor":"Aileron Therapeutics, Inc.","startDate":"2023-01-09","conditions":"Prevention of Chemotherapy-induced Myelosuppression","enrollment":6},{"nctId":"NCT05498636","phase":"PHASE1, PHASE2","title":"SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-10-01","conditions":"DLBCL","enrollment":67},{"nctId":"NCT00280761","phase":"","title":"Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2003-12","conditions":"Colorectal Cancer","enrollment":47},{"nctId":"NCT05489848","phase":"PHASE2, PHASE3","title":"Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-08-20","conditions":"Endometrial Cancer","enrollment":294},{"nctId":"NCT05280626","phase":"PHASE2","title":"First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-03-25","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":100},{"nctId":"NCT02999893","phase":"PHASE1, PHASE2","title":"A Study of APR-246 in Oesophageal Cancer","status":"TERMINATED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2017-04-11","conditions":"Oesophageal Carcinoma","enrollment":5},{"nctId":"NCT01748825","phase":"PHASE1","title":"AZD1775 for Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-12-19","conditions":"Solid Tumors","enrollment":67},{"nctId":"NCT03149679","phase":"PHASE2","title":"The p53 Colorectal Cancer Trial","status":"TERMINATED","sponsor":"Haukeland University Hospital","startDate":"2017-05-09","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation","enrollment":12},{"nctId":"NCT04489706","phase":"NA","title":"Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-06-28","conditions":"Ovarian Cancer, Endometrial Cancer","enrollment":20},{"nctId":"NCT00617409","phase":"PHASE2","title":"To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-10-02","conditions":"Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT02341456","phase":"PHASE1","title":"Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-16","conditions":"Advanced Solid Tumours","enrollment":19},{"nctId":"NCT00899509","phase":"","title":"Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-10","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00005047","phase":"PHASE3","title":"4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"1997-08","conditions":"Bladder Cancer","enrollment":521},{"nctId":"NCT02087241","phase":"PHASE2","title":"Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-03","conditions":"Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT00404339","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Robert Ferris","startDate":"2005-09","conditions":"Head and Neck Cancer","enrollment":17},{"nctId":"NCT02435186","phase":"PHASE2","title":"p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2015-06","conditions":"Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":100},{"nctId":"NCT02429037","phase":"PHASE2","title":"P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2015-05","conditions":"Advanced Head and Neck Cancer","enrollment":60},{"nctId":"NCT02418988","phase":"PHASE2","title":"Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2014-07","conditions":"Advanced Adult Hepatocellular Carcinoma","enrollment":120},{"nctId":"NCT00003880","phase":"PHASE2, PHASE3","title":"Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-02","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":132},{"nctId":"NCT00642746","phase":"PHASE2","title":"Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-03","conditions":"Metastatic Colorectal Cancer","enrollment":16},{"nctId":"NCT00967512","phase":"PHASE2","title":"Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course","status":"WITHDRAWN","sponsor":"Eleos, Inc.","startDate":"2012-01","conditions":"Acute Myelogenous Leukemia","enrollment":""},{"nctId":"NCT00074737","phase":"PHASE2","title":"Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML","status":"COMPLETED","sponsor":"Eleos, Inc.","startDate":"2004-04","conditions":"Acute Myelogenous Leukemia","enrollment":53},{"nctId":"NCT00049218","phase":"PHASE1, PHASE2","title":"Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2003-04","conditions":"Lung Cancer","enrollment":56},{"nctId":"NCT01639885","phase":"PHASE1, PHASE2","title":"Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2011-08","conditions":"Recurrent Ovarian Cancer","enrollment":15},{"nctId":"NCT00017095","phase":"PHASE3","title":"Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-03","conditions":"Breast Cancer","enrollment":1856},{"nctId":"NCT00002919","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1996-11","conditions":"Bladder Cancer","enrollment":30},{"nctId":"NCT00019929","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-08","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00044993","phase":"PHASE2","title":"Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Introgen Therapeutics","startDate":"2002-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00004038","phase":"PHASE1","title":"Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-01","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT01574729","phase":"PHASE2","title":"Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2012-08","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT00017173","phase":"PHASE2","title":"S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2003-02","conditions":"Head and Neck Cancer","enrollment":13},{"nctId":"NCT00902083","phase":"PHASE4","title":"rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2009-06","conditions":"Advanced Oral and Maxillofacial Malignant Tumors","enrollment":600},{"nctId":"NCT00894153","phase":"PHASE4","title":"p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2009-05","conditions":"Neoplasms","enrollment":1200},{"nctId":"NCT00001440","phase":"PHASE1","title":"Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-07","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"chemotherapy plus p53","genericName":"chemotherapy plus p53","companyName":"Shenzhen SiBiono GeneTech Co.,Ltd","companyId":"shenzhen-sibiono-genetech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chemotherapy is used to treat various cancers, including ovarian cancer, primary peritoneal cavity cancer, testicular cancer, ovarian epithelial cancer, and fallopian tube cancer. The chemotherapy regimen typically involves a combination of paclitaxel and carboplatin, with or without the small molecule SCH-58500, which targets the p53 protein.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}